Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 10
Submit an article Journal homepage
1,622
Views
19
CrossRef citations to date
0
Altmetric
Letters to the Editor

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

Heinz LudwigWilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Correspondence[email protected]
,
Meletios A. DimopoulosSchool of Medicine, National and Kapodistrian University of Athens, Athens, Greece;
,
Philippe MoreauUniversity of Nantes, Nantes, France;
,
Wee-Joo ChngNational University Cancer Institute, Singapore; ;National University Health System, Singapore; ;Cancer Science Institute, Singapore; ;National University of Singapore, Singapore;
,
Hartmut GoldschmidtHeidelberg Medical University, Heidelberg, Germany;
,
Roman HájekUniversity Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic;
,
Thierry FaconCHRU Lille Hôpital Claude Huriez, Lille, France;
,
Ludek PourUniversity Hospital Brno, Brno, Czech Republic;
,
Ruben NiesvizkyWeill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA;
,
Albert OriolInstitut Català d’Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain;
,
Laura RosiñolHospital Clínic de Barcelona, Barcelona, Spain;
,
Aleksandr SuvorovFirst Republican Clinical Hospital of Udmurtia, Izhevsk, Russia;
,
Gianluca GaidanoDepartment of Translational Medicine, University of Eastern Piedmont, Novara, Italy;
,
Tomas PikaUniversity Hospital Olomouc, Olomouc, Czech Republic;
,
Katja WeiselUniversitatsklinikum Tubingen, Tubingen, Germany;
,
Vesselina Goranova-MarinovaUniversity Multiprofile Hospital for Active Treatment “Sv. Georgi” and Medical University, Plovdiv, Bulgaria;
,
Antonio PalumboUniversity of Torino, Torino, Italy;
,
Heidi H. GillenwaterOnyx Pharmaceuticals, Inc, an Amgen subsidiary, South San Francisco, CA, USA;
,
Nehal MohamedOnyx Pharmaceuticals, Inc, an Amgen subsidiary, South San Francisco, CA, USA;
,
Sanjay AggarwalOnyx Pharmaceuticals, Inc, an Amgen subsidiary, South San Francisco, CA, USA;
,
Shibao FengOnyx Pharmaceuticals, Inc, an Amgen subsidiary, South San Francisco, CA, USA;
&
Douglas JoshuaRoyal Prince Alfred Hospital, Camperdown, New South Wales, Australia
 show all
Pages 2501-2504 | Received 26 Sep 2016, Accepted 15 Feb 2017, Published online: 17 Mar 2017
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Acknowledgments

The ENDEAVOR study was supported by Onyx Pharmaceuticals, Inc., an Amgen subsidiary. The authors would like to thank Jesse Potash of Amgen Inc. for medical writing assistance.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at http://dx.doi.org/10.1080/10428194.2017.1298755.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.